Polypeptide drugs refer to the specific therapeutic polypeptides extracted by chemical synthesis, gene recombination or animals and plants, and are the specific applications of polypeptides in the field of medicine. The bioactivity of polypeptide is extensive and important, and it can widely act on endocrine system, immune system, digestive system, cardiovascular system, blood system, musculoskeletal system, etc. Therefore, although the development history of polypeptide as a drug is short, it has developed rapidly, and it has become a hot spot of market development.

The growth of China's GDP and the increase of medical expenditure have created a favorable macro environment and promoted the growth of domestic peptide drug market. In 2017, the market scale of peptide medicine industry in China was RMB 63.05 billion, up year on year. With the increase of urbanization rate, per capita disposable income and health concerns, aging population and chronic health problems, the domestic peptide drug market is expected to continue to grow significantly in the future.

Peptide drug industry is a key development area supported by the state, and it is currently in a rapid growth stage. In the past 10 years, the commercial benefits of polypeptide drugs have been rising all the way. Polypeptide drugs will become a major class of important products in the international pharmaceutical market, and its market prospects are very broad.

In the past 10 years, with the rapid development of related technologies, the problem of production cost has been solved, and the production of peptide drugs has entered the golden stage of development. Technologies such as synthesis, purification and liquid combination have promoted the development and production of peptide drugs, and many large biomedical companies are striving to enter this field. Among the multinational pharmaceutical enterprises, Roche and Lilly are more active in this field.

At present, the sales of peptide drugs have accounted for 2% of the whole international drug market, more than 20 billion US dollars. In recent years, the annual growth rate of peptide drug market has reached 20%, far exceeding the annual growth rate of 9% of the overall pharmaceutical market, bringing huge profits to pharmaceutical enterprises.

Compared with the developed countries, there is still a big gap in peptide drug industry in China, and the product structure is also different. At present, the proportion of immune enhancement products in peptide drug market in China is large, such as thymopentin, thymus method, etc., while the share of anti-tumor, diabetes, rare diseases and other varieties is small, the market is not mature, and there is a great development space.

Compared with the international market, China's peptide drug market is still in a rapid growth period. On the one hand, because the peptide drug market in China is not mature, and some large varieties such as cancer and diabetes have less market share, there is a huge growth space; on the other hand, the increasing degree of aging, changes in living habits and environmental deterioration and other factors make the prevalence of cancer, chronic diseases and other factors increase the demand for drugs.

At present, the expansion of the global peptide drug market and the mass listing of generic drugs have also brought growth impetus to the peptide Market in China. At present, China's peptide drug market is dominated by immune products, and the proportion of tumor and diabetes products is not high, so the market is not mature, still in the stage of rapid growth, with unlimited potential in the future.

Peptide drugs have the advantages of "small side effects, good curative effect, low consumption, high output", wide indications and large potential market demand. In a long period in the future, China's peptide drug market will maintain a sustained growth momentum.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.